Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Rituximab Stories

2013-11-14 11:32:11

Adult patients with a type of cancer known as Burkitt lymphoma had excellent long-term survival rates—upwards of 90 percent—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding. Standard treatment for Burkitt lymphoma involves high-dose chemotherapy, which has a high rate of toxicity, including death, and cures only 60 percent of adult patients. This trial was conducted by researchers at the National Cancer Institute (NCI), part of the...

2013-11-07 16:32:03

SUNNYVALE, Calif., Nov. 7, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended September 30, 2013. Financial Results for the Three and Nine Months Ended September 30, 2013 Revenue for the quarter ended September 30, 2013 was $79.1 million compared to $54.7 million for the quarter ended June 30, 2013 and $102.7 million for the quarter ended September 30, 2012. Included in revenue for the three...

2013-11-04 09:13:55

Antibodies against the B cell surface protein CD20 have been used successfully to treat B cell-mediated autoimmune diseases and lymphomas. Antibody binding receptors, called Fc receptors, on other immune cells bind anti-CD20 on coated B cells, which induces B cell deletion through a mechanism that is not clearly understood. In this issue of the Journal of Clinical Investigation, Philippe Bousse and colleagues at the Pasteur Institute in Paris described the fate of B cells in live mice after...

2013-10-31 11:19:00

Remissions last longer, but survival not affected, except in highest risk patients Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine. But early transplantation does appear to be beneficial among a small group of patients who are at the very highest risk, the study found. Lead author is Patrick Stiff, MD, director of...

2013-10-28 08:30:29

Approval of Premium-Priced Novel Agents, Coupled With Rituximab's Continued Dominance, Will Drive a Robust Annual Growth, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2012 to 2022, the launch of five premium-priced new agents--Johnson & Johnson/Janssen/Pharmacyclics' ibrutinib, Gilead Sciences'...

2013-10-15 04:21:01

SEATTLE, Oct. 15, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom (UK), issued second draft guidance on PIXUVRI(®) (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL). NICE's...

2013-10-10 23:23:12

Therapy Class Overview: Rituximab biosimilar is the new market research report added to ReportsnReports.com store. Dallas, Texas (PRWEB) October 10, 2013 Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year. This...

2013-10-10 08:26:50

Oral Agents Could Alter the Treatment Algorithm, After Establishing Clinical Profiles at Least Comparable to TNF-alpha Inhibitors, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market will experience moderate growth over the next decade as sales increase from $12.3 billion in...

2013-09-30 16:25:38

ALEXANDRIA, Va., Sept. 30, 2013 /PRNewswire/ -- Food and Drug Administration (FDA) announced the requirement of a Boxed Warning for the anti-cancer immunosuppressive drugs Arzerra (ofatumumab) and Rituxan (rituximab). The Boxed Warning is specific to the risk of reactivating hepatitis B virus (HBV) in patients who were previously infected with the virus. Use of these drugs in patients with prior HBV infection can result in severe liver damage if the virus is reactivated. The American...

2013-09-24 23:39:05

Achieve is conducting a study to evaluate the safety and efficacy of a new drug versus rituximab in patients with moderately to severely active rheumatoid arthritis (RA). Birmingham, Alabama (PRWEB) September 24, 2013 *To see if you qualify for this RA Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance is required, and you may receive compensation...